Product Information
JANUMET XR 100-1,000 MG TABLET is a brand product labeled by Merck Sharp & Dohme LLC, priced at $10.5559 per EA under NDC 00006008131. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Feb 2, 2012. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
1000; 100 mg/1; mg/1
Manufacturer
Merck Sharp & Dohme LLCNDC
00006008131
Classification
Brand
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATEApproval Type
New Drug (NDA)
FDA Application
NDA202270FDA Approved
2/2/2012
TE Code
AB
On Market Since
2/2/2012
Pharmacological Classes
Price Statistics
The NADAC for JANUMET XR 100-1,000 MG TABLET has been published 671 times since Nov 28, 2013, and over the history we have for it it has risen 25.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $10.5559 per EA |
|---|---|
| All-time high | $18.3351 (May 15, 2024) |
| All-time low | $8.4458 (Nov 28, 2013) |
| 52-week high | $10.5590 |
| 52-week low | $10.5550 |
| Median price | $13.7661 |
| Average price | $13.6374 |
| Largest weekly change | -42.4% (Jan 1, 2025) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 5% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Merck Sharp & Dohme LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
sitagliptin and metformin hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Biguanide class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of JANUMET XR 100-1,000 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for JANUMET XR 100-1,000 MG TABLET, manufactured by Merck Sharp & Dohme LLC, is $10.5559 per EA (NDC 00006008131), effective Sep 30, 2026.
How has the price of JANUMET XR 100-1,000 MG TABLET changed over time?
Over the history we have for it, the NADAC for JANUMET XR 100-1,000 MG TABLET has risen 25.0%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for JANUMET XR 100-1,000 MG TABLET?
Since Nov 28, 2013, the NADAC for JANUMET XR 100-1,000 MG TABLET has ranged from a low of $8.4458 (Nov 28, 2013) to a high of $18.3351 (May 15, 2024), with a median of $13.7661 per EA.
Are there cheaper alternatives to JANUMET XR 100-1,000 MG TABLET?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, ZITUVIMET XR 100-1,000 MG TAB, is $10.0792 per EA — about 5% below JANUMET XR 100-1,000 MG TABLET.
Who manufactures JANUMET XR 100-1,000 MG TABLET?
JANUMET XR 100-1,000 MG TABLET (NDC 00006008131) is labeled by Merck Sharp & Dohme LLC, and CMS classifies it as a brand product.